<DOC>
	<DOCNO>NCT00974233</DOCNO>
	<brief_summary>The purpose research evaluate new combination chemotherapy drug CLL/SLL use drug bendamustine ( intravenous chemotherapy drug ) , rituximab ( intravenous medication call monoclonal antibody ) , lenalidomide ( anti-cancer pill ) . The purpose study see give chemotherapy pill lenalidomide treatment bendamustine rituximab able prolong period time cancer start grow cause symptom .</brief_summary>
	<brief_title>Study Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance Relapsed/Refractory CLL SLL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically confirm , CLL/SLL , document relapsed refractory disease least one prior chemotherapy regimen . In case SLL , patient must least one bidimensionally measurable lesion least ≥1.5 cm measure one dimension . ECOG performance status 02 study entry Laboratory test result within range : ANC &lt; =1500/μL , Platelet count &lt; = 100,000/μL . Patients ANC &lt; 1500/μL plt &lt; 100,000/μL splenomegaly extensive bone marrow involvement etiology cytopenia eligible . creatinine clearance &gt; 60 mL/min determine CockcroftGault calculation . Total bilirubin &lt; = 2X upper limit laboratory normal ( ULN ) . Patients nonclinically significant elevation bilirubin due Gilbert 's disease require meet criterion . Serum transaminases AST ( SGOT ) ALT ( SGPT ) &lt; =5x ULN , Serum alkaline phosphatase ≤5 X ULN . Disease free prior malignancy ≥ 2 year exception basal squamous cell skin carcinoma , carcinoma `` situ '' breast cervix , localized prostate cancer ( treat definitively hormone therapy , radiotherapy , surgery ) . Patients may receive prior therapy bendamustine lenalidomide , must disease refractory bendamustine lenalidomide . Prior therapy rituximab permit , even set rituximab refractory disease . Has receive &gt; 5 line prior therapy disease . Retreatment identical regimen count new regimen . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form comply protocol treatment . Pregnant breast feeding female . Lactating female must agree breast feed take lenalidomide . Prior history current evidence central nervous system leptomeningeal involvement . Use experimental drug therapy within 28 day baseline . Known hypersensitivity thalidomide . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Known positive HIV infectious hepatitis , type B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
</DOC>